Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Refining the impact of genetic evidence on clinical success.

Nature - 1 May 2024

Minikel Eric Vallabh, Painter Jeffery L, Dong Coco Chengliang, Nelson Matthew R

Abstract excerpt

The cost of drug discovery and development is driven primarily by failure1, with only about 10% of clinical programmes eventually receiving approval2-4. We previously estimated that human genetic evidence doubles the success rate from clinical development to approval5. In this study we leverage the growth in genetic evidence over the past decade to better understand the characteristics that distinguish clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Drug Approval
Share to Drug Discovery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Probability

Share to Time Factors

Share to Treatment Failure

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 38632401
DOI: 10.1038/s41586-024-07316-0
PMCID: PMC11096124

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Refining the impact of genetic evidence on clinical success.PMID 38632401Read ↗

Refining the impact of genetic evidence on clinical successSemantic proximity Read ↗

The support of human genetic evidence for approved drug indications.Semantic proximity Read ↗

The impact on clinical success from the 23andMe cohortSemantic proximity Read ↗

Human genetics as a foundation for innovative drug developmentSemantic proximity Read ↗

Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approvalSemantic proximity Read ↗

Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval.Semantic proximity Read ↗

Flipping the odds of drug development success through human genomicsSemantic proximity Read ↗

Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations.Semantic proximity Read ↗

Genetics in drug discovery and development: challenge and promise of individualizing treatment in common complex diseases.Semantic proximity Read ↗

Retrospective evaluation of human genetic evidence for clinical trial success using Mendelian randomization and machine learningSemantic proximity Read ↗

Human genetic evidence enriched for side effects of approved drugsSemantic proximity Read ↗

Translating Human Genetics into Novel Drug Targets.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.